Role of Fibrinolysis in Sepsis

 

 Buy Article Permissions and Reprints

Abstract

Sepsis, defined as infection-induced systemic inflammatory response syndrome, invariably leads to hemostatic abnormalities ranging from insignificant coagulopathy to disseminated intravascular coagulation (DIC). The inflammation-induced activation of coagulation, the downregulation of physiologic anticoagulant pathways, and impairment of fibrinolysis play a pivotal role in the pathogenesis of microvascular fibrin thrombosis and multiple organ dysfunction syndrome (MODS) in DIC associated with sepsis. The balance between tissue plasminogen activator and plasminogen activator inhibitor-1 mainly regulates fibrinolytic activity. Thrombin-activatable fibrinolysis inhibitor and neutrophil elastase also modulate fibrinolysis. Dynamic changes in these molecules are deeply involved in the pathomechanisms of the impairment of fibrinolysis, leading to MODS in DIC associated with sepsis. Evidence indicates that physical entrapment of bacteria by fibrin at the site of infection may limit their capacity to disseminate into nearby tissues, organs, and systemic circulation. Under this circumstance, impairment of fibrinolysis has protective role in the host defense. Given the protective and pathologic potential of fibrinolysis during sepsis, therapeutics that control DIC as a systemic syndrome, while maintaining the host defense at the infectious foci, are required for the protection against both the development of MODS and for the host defense mechanisms.

• References

• 1 Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definition for sepsis and organ failure and guidelines for the use innovative therapies in sepsis. Crit Care Med 1992; 20 (6) 864-874
  CrossrefPubMedGoogle Scholar
• 2 Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003; 16 (1–2) 43-47
  CrossrefPubMedGoogle Scholar
• 3 Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med 2010; 38 (2, Suppl): S35-S42
  CrossrefPubMedGoogle Scholar
• 4 Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273 (2) 117-123
  CrossrefPubMedGoogle Scholar
• 5 Maas C, Oschatz C, Renné T. The plasma contact system 2.0. Semin Thromb Hemost 2011; 37 (4) 375-381
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Nickel KF, Renné T. Crosstalk of the plasma contact system with bacteria. Thromb Res 2012; 130 (Suppl. 01) S78-S83
  CrossrefPubMedGoogle Scholar
• 7 Hack CE. Fibrinolysis in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27 (6) 633-638
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Plow EF. The contribution of leukocyte proteases to fibrinolysis. Blut 1986; 53 (1) 1-9
  CrossrefPubMedGoogle Scholar
• 9 Plow EF. Leucocyte elastase release during blood coagulation. J Clin Invest 1982; 69 (3) 564-572
  CrossrefPubMedGoogle Scholar
• 10 Kohno I, Inuzuka K, Itoh Y , et al. A monoclonal antibody specific to the granulocyte-derived elastase-fragment D species of human fibrinogen and fibrin: its application to the measurement of granulocyte-derived elastase digests in plasma. Blood 2000; 95 (5) 1721-1728
  PubMedGoogle Scholar
• 11 Bouma BN, Meijers JCM. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003; 1 (7) 1566-1574
  CrossrefPubMedGoogle Scholar
• 12 Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost 2007; 5 (Suppl. 01) 24-31
  CrossrefPubMedGoogle Scholar
• 13 Bergmann S, Hammerschmidt S. Fibrinolysis and host response in bacterial infections. Thromb Haemost 2007; 98 (3) 512-520
  PubMedGoogle Scholar
• 14 Adib-Conquy M, Cavaillon JM. Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett 2007; 581 (19) 3723-3733
  CrossrefPubMedGoogle Scholar
• 15 de Jong HK, van der Poll T, Wiersinga WJ. The systemic pro-inflammatory response in sepsis. J Innate Immun 2010; 2 (5) 422-430
  CrossrefPubMedGoogle Scholar
• 16 Creagh EM, O'Neill LAJ. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006; 27 (8) 352-357
  CrossrefPubMedGoogle Scholar
• 17 Russell JA, Boyd J, Nakada T, Thair S, Walley KR. Molecular mechanisms of sepsis. Contrib Microbiol 2011; 17: 48-85
  PubMedGoogle Scholar
• 18 Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003; 1 (7) 1343-1348
  CrossrefPubMedGoogle Scholar
• 19 Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85 (6) 958-965
  PubMedGoogle Scholar
• 20 Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res 2012; 129 (3) 290-295
  CrossrefPubMedGoogle Scholar
• 21 Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320 (18) 1165-1172
  CrossrefPubMedGoogle Scholar
• 22 van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76 (12) 2520-2526
  CrossrefPubMedGoogle Scholar
• 23 de Boer JP, Creasy AA, Chang A , et al. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli. Circ Shock 1993; 39 (1) 59-67
  PubMedGoogle Scholar
• 24 Biemond BJ, Levi M, Ten Cate H , et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond) 1995; 88 (5) 587-594
  CrossrefPubMedGoogle Scholar
• 25 Sawdey MS, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem 1989; 264 (18) 10396-10401
  PubMedGoogle Scholar
• 26 Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991; 88 (4) 1346-1353
  CrossrefPubMedGoogle Scholar
• 27 van der Poll T, Levi M, Büller HR , et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174 (3) 729-732
  CrossrefPubMedGoogle Scholar
• 28 Jansen PM, Boermeester MA, Fischer E , et al. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood 1995; 86 (3) 1027-1034
  PubMedGoogle Scholar
• 29 Stouthard JML, Levi M, Hack CE , et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76 (5) 738-742
  PubMedGoogle Scholar
• 30 van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27 (6) 639-651
  Article in Thieme ConnectPubMedGoogle Scholar
• 31 Pralong G, Calandra T, Glauser MP , et al. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 1989; 61 (3) 459-462
  PubMedGoogle Scholar
• 32 Páramo JA, Pérez JL, Serrano M, Rocha E. Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Thromb Haemost 1990; 64 (1) 3-6
  PubMedGoogle Scholar
• 33 Dofferhoff AS, Bom VJJ, de Vries-Hospers HG , et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992; 20 (2) 185-192
  CrossrefPubMedGoogle Scholar
• 34 Mesters RM, Flörke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996; 75 (6) 902-907
  Article in Thieme ConnectPubMedGoogle Scholar
• 35 Robbie LA, Dummer S, Booth NA, Adey GD, Bennett B. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis. Br J Haematol 2000; 109 (2) 342-348
  CrossrefPubMedGoogle Scholar
• 36 Madoiwa S, Nunomiya S, Ono T , et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol 2006; 84 (5) 398-405
  CrossrefPubMedGoogle Scholar
• 37 Francis Jr RB, Seyfert U. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: clinicopathologic correlations. J Lab Clin Med 1987; 110 (5) 541-547
  PubMedGoogle Scholar
• 38 Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996; 75 (2) 224-228
  PubMedGoogle Scholar
• 39 Hesselvik JF, Blombäck M, Brodin B, Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med 1989; 17 (8) 724-733
  CrossrefPubMedGoogle Scholar
• 40 Raaphorst J, Johan Groeneveld AB, Bossink AWJ, Erik Hack C. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001; 86 (2) 543-549
  PubMedGoogle Scholar
• 41 Asakura H, Ontachi Y, Mizutani T , et al. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med 2001; 29 (6) 1164-1168
  CrossrefPubMedGoogle Scholar
• 42 Kawamura T, Okada N, Okada H. Elastase from activated human neutrophils activates procarboxypeptidase R. Microbiol Immunol 2002; 46 (3) 225-230
  PubMedGoogle Scholar
• 43 Binette TM, Taylor Jr FBJ, Peer G, Bajzar L. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood 2007; 110 (9) 3168-3175
  CrossrefPubMedGoogle Scholar
• 44 Ravindranath TM, Goto M, Iqbal O , et al. Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. Clin Appl Thromb Hemost 2007; 13 (4) 362-368
  CrossrefPubMedGoogle Scholar
• 45 Wang YX, da Cunha V, Vincelette J , et al. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Part II. Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 2007; 97 (1) 54-61
  PubMedGoogle Scholar
• 46 Muto Y, Suzuki K, Iida H , et al. EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats. Crit Care Med 2009; 37 (5) 1744-1749
  CrossrefPubMedGoogle Scholar
• 47 Kim PY, Kim PYG, Taylor Jr FBJ, Nesheim ME. Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis. J Thromb Thrombolysis 2012; 33 (4) 412-415
  CrossrefPubMedGoogle Scholar
• 48 Watanabe R, Wada H, Watanabe Y , et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001; 104 (1) 1-6
  CrossrefPubMedGoogle Scholar
• 49 Chen CC, Lee KD, Gau JP , et al. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation. Ann Hematol 2005; 84 (10) 675-680
  CrossrefPubMedGoogle Scholar
• 50 Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118 (2) 205-212
  CrossrefPubMedGoogle Scholar
• 51 Emonts M, de Bruijne ELE, Guimarães AHC , et al. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost 2008; 6 (2) 268-276
  CrossrefPubMedGoogle Scholar
• 52 Skeppholm M, Wallén NH, Mobarrez F, Sollevi A, Soop A, Antovic JP. Inflammation and thrombin generation causes increased thrombin activatable fibrinolysis inhibitor levels in experimental human endotoxemia. Blood Coagl Fibrinol 2009; 20: 611-613
  PubMedGoogle Scholar
• 53 Hayakawa M, Sawamura A, Gando S, Jesmin S, Naito S, Ieko M. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis. Thromb Res 2012; 130 (6) 906-913
  CrossrefPubMedGoogle Scholar
• 54 Sato T, Miwa T, Akatsu H , et al. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000; 165 (2) 1053-1058
  PubMedGoogle Scholar
• 55 Morser J, Gabazza EC, Myles T, Leung LL. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?. J Thromb Haemost 2010; 8 (5) 868-876
  PubMedGoogle Scholar
• 56 Renckens R, Roelofs JJTH, ter Horst SAJ , et al. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 2005; 175 (10) 6764-6771
  CrossrefPubMedGoogle Scholar
• 57 van Gorp ECM, Minnema MC, Suharti C , et al. Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever. Br J Haematol 2001; 113 (1) 94-99
  CrossrefPubMedGoogle Scholar
• 58 Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40 (7) 431-442
  CrossrefPubMedGoogle Scholar
• 59 Ceresa E, Brouwers E, Peeters M, Jern C, Declerck PJ, Gils A. Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol 2006; 26 (2) 423-428
  PubMedGoogle Scholar
• 60 Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8 (10) 776-787
  CrossrefPubMedGoogle Scholar
• 61 Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: stranger or partners in the crime?. Trends Immunol 2010; 28: 184-192
  PubMedGoogle Scholar
• 62 Amara U, Flierl MA, Rittirsch D , et al. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185 (9) 5628-5636
  CrossrefPubMedGoogle Scholar
• 63 Leung LLK, Myles T, Nishimura T, Song JJ, Robinson WH. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol 2008; 45 (16) 4080-4083
  CrossrefPubMedGoogle Scholar
• 64 Kamikura Y, Wada H, Nobori T , et al. Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with deep vein thrombosis. Thromb Res 2005; 115 (1–2) 53-57
  CrossrefPubMedGoogle Scholar
• 65 Gando S, Kameue T, Sawamura A, Hayakawa M, Hoshino H, Kubota N. An alternative pathway for fibrinolysis is activated in patients who have undergone cardiopulmonary bypass surgery and major abdominal surgery. Thromb Res 2007; 120 (1) 87-93
  CrossrefPubMedGoogle Scholar
• 66 Matsumoto T, Wada H, Nobori T , et al. Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with disseminated intravascular coagulation. Clin Appl Thromb Hemost 2005; 11 (4) 391-400
  CrossrefPubMedGoogle Scholar
• 67 Madoiwa S, Tanaka H, Nagahama Y , et al. Degradation of cross-linked fibrin by leukocyte elastase as alternative pathway for plasmin-mediated fibrinolysis in sepsis-induced disseminated intravascular coagulation. Thromb Res 2011; 127 (4) 349-355
  CrossrefPubMedGoogle Scholar
• 68 Gando S, Hayakawa M, Sawamura A , et al. The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation. Thromb Res 2007; 121 (1) 67-73
  CrossrefPubMedGoogle Scholar
• 69 Johnson LL, Berggren KN, Szaba FM, Chen W, Smiley ST. Fibrin-mediated protection against infection-stimulated immunopathology. J Exp Med 2003; 197 (6) 801-806
  CrossrefPubMedGoogle Scholar
• 70 Sodeinde OA, Sample AK, Brubaker RR, Goguen JD. Plasminogen activator/coagulase gene of Yersinia pestis is responsible for degradation of plasmid-encoded outer membrane proteins. Infect Immun 1988; 56 (10) 2749-2752
  PubMedGoogle Scholar
• 71 Frick IM, Björck L, Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb Haemost 2007; 98 (3) 497-502
  PubMedGoogle Scholar
• 72 Frick IM, Åkesson P, Herwald H , et al. The contact system—a novel branch of innate immunity generating antibacterial peptides. EMBO J 2006; 25 (23) 5569-5578
  CrossrefPubMedGoogle Scholar
• 73 Renckens R, Pater JM, van der Poll T. Plasminogen activator inhibitor type-1-deficient mice have an enhanced IFN-gamma response to lipopolysaccharide and staphylococcal enterotoxin B. J Immunol 2006; 177 (11) 8171-8176
  PubMedGoogle Scholar
• 74 Renckens R, Roelofs JJTH, Bonta PI , et al. Plasminogen activator inhibitor type 1 is protective during severe gram-negative pneumonia. Blood 2007; 109 (4) 1593-1601
  CrossrefPubMedGoogle Scholar
• 75 Kager LM, Wiersinga WJ, Roelofs JJ , et al. Plasminogen activator inhibitor type I contributes to protective immunity during experimental gram-negative sepsis (melioidosis). J Thromb Haemost 2011; 9 (10) 2020-2028
  CrossrefPubMedGoogle Scholar
• 76 Luo D, Szaba FM, Kummer LW , et al. Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica . J Immunol 2011; 187 (4) 1866-1876
  CrossrefPubMedGoogle Scholar
• 77 Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way?. Crit Care Med 2012; 40 (9) 2704-2708
  CrossrefPubMedGoogle Scholar
• 78 Taylor Jr FBJ, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86 (5) 1327-1330
  Article in Thieme ConnectPubMedGoogle Scholar